Compare ROP & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROP | ONC |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4B | 31.4B |
| IPO Year | 2002 | N/A |
| Metric | ROP | ONC |
|---|---|---|
| Price | $317.09 | $300.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | ★ $492.60 | $385.10 |
| AVG Volume (30 Days) | ★ 1.0M | 200.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.87 | N/A |
| Revenue | ★ $7,902,500,000.00 | N/A |
| Revenue This Year | $8.80 | $723.76 |
| Revenue Next Year | $6.73 | $15.04 |
| P/E Ratio | ★ $65.89 | $614.06 |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $305.96 | $239.25 |
| 52 Week High | $576.49 | $385.22 |
| Indicator | ROP | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 46.33 |
| Support Level | $309.52 | $295.20 |
| Resistance Level | $364.24 | $325.40 |
| Average True Range (ATR) | 9.29 | 7.90 |
| MACD | -0.99 | -0.32 |
| Stochastic Oscillator | 22.22 | 32.46 |
Roper Technologies is a holding company focused on acquiring, managing, and developing niche market-leading technology businesses. The company operates a decentralized business model whereby each portfolio company operates independently from the others. Roper positions itself as a free cash flow compounder, whereby excess free cash flow generated by its portfolio businesses is repatriated to the parent company, which is then utilized to acquire additional businesses. Presently, the company operates 30 distinct businesses with over three-fourths of the revenue coming from software products and over two-thirds of revenue coming from recurring and reoccurring sources.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.